Susceptibility of <i>Escherichia coli</i> from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea

Seo, Minah; Kim, Seong Jong; Kim, Yeonjae; Kim, Jieun; Choi, Thomas Y.; Kang, Jung Oak; Wie, Seong Heon; Ki, Moran; Cho, Young Kyun; Lim, Seung Kwan; Lee, Jin Seo; Kwon, Ki Tae; Lee, Hyuck; Cheong, Hee Jin; Park, Dae Won; Ryu, Seong Yeol; Chung, Moon Hyun; Pai, Hyunjoo

doi:10.3346/jkms.2014.29.8.1178

Cited by 29 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the fosfomycin resistance rate was estimated to be 6.7%, which is somewhat higher than that previously reported in South Korea [14][15][16][17]. This study identified different genotypes among 19 fosfomycin-resistant E. coli isolates, suggesting that most of these isolates might emerge sporadically.…”

Section: Discussioncontrasting

confidence: 51%

“…The current resistance rate of E. coli to fosfomycin is estimated to be lower than 5%, and lower than 10% among extended spectrum β-lactamase (ESBL) producers worldwide [11][12][13]. In South Korea, the fosfomycin resistance rate has been reported to be up to 3% in clinical E. coli isolates, and up to 7% among ESBL producers [14][15][16][17]. However, only a few studies have explored the mechanisms of fosfomycin resistance and the genotypes of fosfomycin-resistant E. coli isolates in South Korea.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics

Seok

Choi

et al. 2020

Antibiotics

Self Cite

View full text Add to dashboard Cite

We investigated fosfomycin susceptibility in Escherichia coli clinical isolates from South Korea, including community-onset, hospital-onset, and long-term care facility (LTCF)-onset isolates. The resistance mechanisms and genotypes of fosfomycin-resistant isolates were also identified. Finally, the in vitro efficacy of combinations of fosfomycin with other antibiotics were examined in susceptible or extended spectrum β-lactamase (ESBL)-producing E. coli isolates. The fosfomycin resistance rate was 6.7% and was significantly higher in LTCF-onset isolates than community-onset and hospital-onset isolates. Twenty-one sequence types (STs) were identified among 19 fosfomycin-resistant E. coli isolates, showing diverse genotypes. fosA3 was found in only two isolates, and diverse genetic variations were identified in three genes associated with fosfomycin resistance, namely, GlpT, UhpT, and MurA. Some fosfomycin-resistant E. coli isolates carried no mutations. In vitro time-kill assays showed that fosfomycin alone did not exhibit an excellent killing activity, compared with ciprofloxacin in susceptible isolates and with ertapenem in ESBL producers. However, combining fosfomycin with cefixime or piperacillin-tazobactam eradicated susceptible or ESBL-producing isolates, respectively, even with 0.5× minimum inhibitory concentrations. Overall, we found a relatively high fosfomycin resistance rate in E. coli isolates from South Korea. Based on their genotypes and resistance mechanisms, most of the fosfomycin-resistant E. coli isolates might occur independently. Antibiotic combinations with fosfomycin could be a suitable therapeutic option for infections caused by E. coli isolates.

show abstract

Section: Discussioncontrasting

confidence: 51%

Section: Introductionmentioning

confidence: 99%

Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics

Seok

Choi

et al. 2020

Antibiotics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thirdly, fluoroquinolone was not administered as an initial intravenous antibiotic, although it was recommended for the treatment of hospitalized women with APN in most guidelines [ 21 , 22 ]. In this study, fluoroquinolone was not initially administered due to the relatively high rates of fluoroquinolone-resistant E. coli present in Korea, and was preserved for more important uses than the treatment of UTIs [ 3 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

A comparison of the clinical characteristics of elderly and non-elderly women with community-onset, non-obstructive acute pyelonephritis

Chang

Kim

Noh

et al. 2015

Korean J Intern Med

Self Cite

View full text Add to dashboard Cite

Background/AimsAcute pyelonephritis (APN) is the most common cause of community-onset bacteremia in hospitalized elderly patients. The objectives of this study were to investigate the differences in the clinical and microbiological data of hospitalized elderly and non-elderly women with community-onset APN.MethodsWomen with community-onset APN as a discharge diagnosis were identified from January 2004 to December 2013 using an electronic medical records system. We compared the clinical and microbiologic data in elderly and non-elderly women with community-onset APN due to Enterobacteriaceae.ResultsOf the 1,134 women with community-onset APN caused by Enterobacteriaceae, 443 were elderly and 691 were non-elderly women. The elderly group had a lower frequency of upper and lower urinary tract symptoms/signs than the non-elderly. The incidence of bacteremia, extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, patients with a C-reactive protein (CRP) level ≥ 15 mg/dL, and patients with a leukocyte count ≥ 15,000/mm3 in the blood, were significantly higher in the elderly group than in the non-elderly group. The proportion of patients requiring hospitalization for 10 days or more was significantly higher in the elderly group compared to the non-elderly group (51.5% vs. 26.2%, p < 0.001). The clinical cure rates at 4 to 14 days after the end of therapy were 98.3% (338/344) and 97.4% (519/533) in the elderly and non-elderly groups, respectively (p = 0.393).ConclusionsElderly women with APN exhibit higher serum CRP levels, a higher frequency of bacteremia, a higher proportion of ESBL-producing uropathogens, and require a longer hospitalization than non-elderly women, although these patients may not complain of typical urinary symptoms.

show abstract

“…Seo et al [17] reported in 2014 reported that fosfomycin susceptibility on community-acquired UTI was 100% (346/346). With respect of ESBL control, Cho et al [18] tested 277 isolates of ESBL-positive E. coli and Klebsiella pneumoniae from urine samples of patients with UTI, and showed that 243 out of the 277 (87.7%) isolates were susceptible to fosfomycin.…”

Section: Discussionmentioning

confidence: 99%

The Antibiotic Susceptibility of Escherichia coli from Community-Acquired Uncomplicated Urinary Tract Infection: A Focused on Fosfomycin

Choe

Lee

Chang

et al. 2017

Urogenit Tract Infect

View full text Add to dashboard Cite

Purpose:To assess the antibiotic susceptibility of Escherichia coli from community-acquired uncomplicated urinary tract infection (UTI). Materials and Methods: Between August and December of 2015, confirmed cases of E. coli as a pathogen of community-acquired uncomplicated UTI were collected and assessed for antibiotic susceptibility in 10 designated hospitals. Additional fosfomycin susceptibility test was performed by a central laboratory using the disk diffusion method. Results: A total of 347 E. coli isolates were collected from urine samples of community-acquired uncomplicated UTIs patients. The susceptibility rates of antibiotics were as follows: amikacin 100.0% (347), imipenem 100.0% (347), ciprofloxacin 57.1% (198), cefotaxime 74.9% (260), ampicillin 30.0% (104), trimethoprim/sulfamethoxazole 66.9% (232), and fosfomycin 98.0% (340). All fosfomycin-resistant E. coli isolates were extended-spectrum -lactamase (ESBL)-producing. In 85 cases of ESBL-producing E. coli, the fosfomycin susceptibility rate was 91.8% (78/85). Conclusions: Fosfomycin may be a useful option for the treatment of community-acquired uncomplicated UTIs. Further studies evaluating the role of fosfomycin in the treatment of UTIs and its clinical efficacy are necessary.

show abstract

Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea

Cited by 29 publications

References 12 publications

Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics

Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics

A comparison of the clinical characteristics of elderly and non-elderly women with community-onset, non-obstructive acute pyelonephritis

The Antibiotic Susceptibility of Escherichia coli from Community-Acquired Uncomplicated Urinary Tract Infection: A Focused on Fosfomycin

Contact Info

Product

Resources

About